Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TERT Promoter Mutation as a Potential Predictive Biomarker in BCG-Treated Bladder Cancer Patients.

International journal of molecular sciences - 31 Jan 2020

Batista Rui, Lima Luís, Vinagre João, Pinto Vasco, Lyra Joana, Máximo Valdemar, Santos Lúcio, Soares Paula

Abstract excerpt

Telomerase reverse transcriptase gene promoter (TERTp) mutations are recognized as one of the most frequent genetic events in bladder cancer (BC). No studies have focused on the relevance of TERTp mutations in the specific group of tumors treated with Bacillus Calmette-Guérin (BCG) intravesical therapy. Methods - 125 non muscle invasive BC treated with BCG therapy (BCG-NMIBC) were screened for TERTp mutations,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BCG Vaccine
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Grading

Share to Neoplasm Staging

Share to Receptor, Fibroblast Growth Factor, Type 3

Share to Telomerase

Share to Treatment Outcome

Share to Urinary Bladder Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 32023888
DOI: 10.3390/ijms21030947
PMCID: PMC7037401

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TERT Promoter Mutation as a Potential Predictive Biomarker in BCG-Treated Bladder Cancer Patients.PMID 32023888Read ↗

The role of telomerase reverse transcriptase (TERT) promoter mutations in prognosis in bladder cancer.Semantic proximity Read ↗

Biological and clinical perspectives of TERT promoter mutation detection on bladder cancer diagnosis and management.Semantic proximity Read ↗

TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism.Semantic proximity Read ↗

Activating Telomerase TERT Promoter Mutations and Their Application for the Detection of Bladder Cancer.Semantic proximity Read ↗

Prognostic Factors of Non-Muscle Invasive Bladder Cancer: A Study Based on Next-generation SequencingSemantic proximity Read ↗

Prognostic implication of TERT promoter mutation and circulating tumor cells in muscle-invasive bladder cancer.Semantic proximity Read ↗

TERT Promoter Mutations as Simple and Non-Invasive Urinary Biomarkers for the Detection of Urothelial Bladder Cancer in a High-Risk Region.Semantic proximity Read ↗

Implications of TERT promoter mutations and telomerase activity in solid tumors with a focus on genitourinary cancers.Semantic proximity Read ↗

A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy.Semantic proximity Read ↗

Combined genetic and epigenetic alterations of the TERT promoter affect clinical and biological behavior of bladder cancerSemantic proximity Read ↗

Non-invasive prediction of recurrence in bladder cancer by detecting somatic TERT promoter mutations in urine.Semantic proximity Read ↗

Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Guérin Immunotherapy in Non-Muscle-Invasive Bladder Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.